Research.Patient.info
Neovascular Age-related Macular Degeneration (wet AMD) research hub
2 indexed studies · 2 currently recruiting
- recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
This study is testing a new treatment called OPT-302, given alongside an existing treatment (Eylea), for a serious eye condition called 'wet' Age-related Macular Degeneration (AMD). Doctors want to see if combining these treatments helps people see better than Eylea alone.
Czechia · Bulgaria · Croatia - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
This study looks at a new drug, OPT-302, combined with an existing treatment (Lucentis) for 'wet' age-related macular degeneration (AMD). It aims to see if the combination works better than Lucentis alone to improve or maintain vision over one year.
Hungary · Denmark · Czechia